OCT 28, 2021 5:00 AM PDT

Unlocking a New Target to Treat Gut Inflammation

WRITTEN BY: Tara Fernandez

Immunologists have uncovered a molecular switch in T cells that serves as a prime target for therapeutics against inflammatory bowel disease, or IBS. 

Over 10 percent of the population is affected by IBS, yet we still don’t have a clear picture of the biology underlying the condition. The root cause is likely not one, but a combination of factors, including chronic inflammation, leaky gut syndrome, changes in the intestinal microbiome, and hypersensitivity to certain foods. 

On the hunt to bridge knowledge gaps in the field, a team of researchers took a closer look at an immune molecule known as the transmembrane activator and calcium modulator and cyclophilin ligand interactor, or TACI. 

Scientists had previously observed that TACI is expressed on antibody-producing B cells. However, researchers believed that TACI might also be transiently expressed on T cells, influencing their activity during autoimmune disorders. 

In their study, researchers used a knockout mouse model (lacking the TACI gene) to investigate immune cell dynamics during elevated gut inflammation. They found that the loss of TACI elevated the risk of severe flare-ups in the gut lining. Animals lacking TACI also spiraled more rapidly after IBS onset: they lost weight and showed signs of extensive damage to the colon lining. Many more TACI-negative animals did not survive the extreme IBS symptoms compared to the control group. 

Ultimately, the researchers demonstrate that TACI is a potent orchestrator of gut inflammation, and stimulating TACI expression in IBS patients' immune cells may help relieve symptoms. 

According to the researchers, the implications of their findings go beyond IBS. “Besides extending the diverse roles TACI plays in various immune cell types to CD4+ T cells, our findings advance the understanding of the context-specific mechanisms governing TACI function that will inform the development of new therapeutics to target TACI for the amelioration of autoimmune diseases, infection, and cancer,” wrote the authors. 

 

 


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 05, 2021
Immunology
Monkey Gene Snares Viruses, Inspires Future Antivirals
OCT 05, 2021
Monkey Gene Snares Viruses, Inspires Future Antivirals
Many of the deadly viruses that affect humans—including Ebola and HIV—have animal origins. These infectious ...
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
NOV 18, 2021
Immunology
Could Maternal Antibodies Contribute to Autism Development?
NOV 18, 2021
Could Maternal Antibodies Contribute to Autism Development?
Pregnant mothers pass on oxygen and nutrients to their developing babies while shuttling away waste products from the fe ...
NOV 21, 2021
Microbiology
Rare Genetic Variant Can Make People Susceptible to Bird Flu H7N9
NOV 21, 2021
Rare Genetic Variant Can Make People Susceptible to Bird Flu H7N9
Zoonosis is a serious health concern, as the COVID-19 pandemic has shown. Viruses that infect one species can acquire ge ...
DEC 02, 2021
Microbiology
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
DEC 02, 2021
A 'Bispecific Antibody' to Fight Crimean-Congo Hemorrhagic Fever
Crimean-Congo hemorrhagic fever (CCHF) is a deadly disease, which is fatal in about 30 percent of cases. It's caused ...
JAN 13, 2022
Immunology
Convalescent Plasma Therapy 'Keeps up' With COVID Variants
JAN 13, 2022
Convalescent Plasma Therapy 'Keeps up' With COVID Variants
A recent study has demonstrated that COVID-19 convalescent plasma treatment (or blood from individuals who have recovere ...
Loading Comments...